Thorough ECG (QT) study of EVK-001 (metoclopramide nasal spray) in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 May 2016
Price : $35 *
At a glance
- Drugs Metoclopramide (Primary)
- Indications Diabetic gastroparesis
- Focus Adverse reactions; Registrational
- Sponsors Evoke Pharma
- 24 May 2016 According to Evoke Pharma media release, this study was designed in accordance with published FDA and ICH guidance on the clinical evaluation of QT/QTc interval prolongation and the proarrhythmic potential of non-cardiac drugs.
- 24 May 2016 Data from this study were presented at Digestive Disease Week (DDW) 2016, as per Evoke Pharma media release.
- 17 Feb 2016 According to an Evoke Pharma media release, results from this study will be presented at the Digestive Disease Week 2016.